Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to significantly improve the metabolic indicators and protect the kidneys and heart of patients with or without type 2 diabetes mellitus. The possible mechanisms mediating these cardiorenal benefits are extensively investigated, with emerging data indicating the involvement of metabolic reprogramming. SGLT2 inhibitors are responsible for the systemic reprogramming of metabolism to a fasting-like metabolic paradigm by switching from carbohydrates to other energetic substrates.
Join the eminent Endocrinologist, Dr. Ihab El Tayeb , in an exclusive session, where he will discuss “ Cardiorenal Protection with SGLT2 Inhibitors in Diabetes ” on 2 1 st May 2023 , 3:00 PM IST onwards . Session highlights Mechanism of SGLT2 inhibitors Contraindications of SGLT2 inhibitors The role of SGLT2 in the management of diabetes …
